Targeting high-need diseases with novel therapies is a winning formula - Deloitte

Prioritising unmet needs, novel MOAs, and the latest technology can boost pharma returns, says Deloitte report. See how Kimer Med’s antiviral pipeline development aligns with these growth drivers.

To read the whole report click here.

Global business consultancy, Deloitte, recently published their fifteenth annual report on biopharmaceutical performance and innovation, with a focus on understanding the critical pipeline decisions that drive business growth, enhanced return on R&D, and ultimately, deliver new therapies to the patients that need them.

The long-running report series, called ‘Be brave, be bold - measuring the return from pharmaceutical innovation’, uses a consistent methodology to identify and track key trends and drivers of success for the world’s 20 largest biopharma companies (by R&D expenditure).

Deloitte’s analysis highlights the importance of some key strategic approaches to pipeline development that offer a competitive advantage and improve the likelihood of success. These include: 

• prioritising areas of high unmet medical need

• pursuing novel mechanisms of action (MOAs), and

• utilising cutting-edge technologies like AI.

The report also identified the advantage of portfolio diversification into less-saturated therapy areas, citing intense competition for suitable clinical trial sites and participants, driving up costs and increasing the time to get drugs to market.

Although targeting areas of unmet need inherently involves greater complexity and risk than incremental improvements on existing drugs, the report argues that the rewards for companies who are bold enough to pursue them can be substantial, both financially and in terms of improving global health outcomes. 

It also highlights some compelling advantages of pursuing assets with a novel mechanism of action. These include:

•  improved efficacy

• better patient outcomes

• greater share of eligible patients (reduced competition), and

• higher return on investment.

All this is music to our ears at Kimer Med, as we continue to develop our pipeline of novel broad-spectrum antiviral drug candidates with downstream out-licensing in mind. 

With our unique approach, and the majority of our successful results against viruses with no currently approved treatment, it’s encouraging to see how well our business strategy aligns with needs of the wider industry.

The optimisation of our antiviral platform and the creation of a valuable pipeline of drug candidates is key to ensuring Kimer Med’s sustainable growth, and enabling us to successfully deliver on our mission to get life-changing antiviral medicines to the millions of people who need them.